您当前的位置：
首页 >
文章列表页 >
Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer
更新时间：2026-04-24

    • Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer

    • ZHONGGUO YAOFANG   Vol. 37, Issue 8, Pages: 1033-1038(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.08.11    

      CLC： R956

    • Received：07 January 2026，

      Revised：2026-04-09，

      Accepted：10 April 2026，

      Published：30 April 2026

    移动端阅览

  • LIU Ran,GAO Shengnan,LI Congxin,et al.Pharmacoeconomic evaluation of culmerciclib combined with fulvestrant in the second-line treatment of HR+/HER2－ locally advanced or metastatic breast cancer[J].ZHONGGUO YAOFANG,2026,37(08):1033-1038. DOI： 10.6039/j.issn.1001-0408.2026.08.11.

  •  
  •  

0

Views

0

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Pharmacoeconomic evaluation of additional use of daratumumab in the treatment of transplant-ineligible newly diagnosed multiple myeloma
Pharmacoeconomic evaluation of zolbetuximab combined with chemotherapy as first-line treatment for CLDN18.2-positive and HER2-negative advanced gastric cancer
Study on the effect and mechanism of modified Yanghe decoction on bone destruction in rats with breast cancer bone metastasis
Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma
Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections

Related Author

JIA Linlin
HU Mengxue
GAO Hongting
HOU Yanhong
HUANG Ying
LI Su
WANG Yan
HUANG Danxue

Related Institution

Dept. of Thoracic Radiation Oncology， Cancer Hospital of Dalian University of Technology/Liaoning Cancer Hospital & Institute
Dept. of Pharmacy， Cancer Hospital of Dalian University of Technology/Liaoning Cancer Hospital & Institute
Dept. of Oncology， Wuhan Hospital of Traditional Chinese Medicine
Dept. of Orthopedics and Traumatology， Wuhan Hospital of Traditional Chinese Medicine
Dept. of Clinical Pharmacy， Hebei Medical University Third Hospital
0